NCT06768619 - Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 20, 2020

Primary Completion Date

April 27, 2020

Study Completion Date

April 27, 2023

Conditions

Thrombocytopenia

Interventions

DRUG

Group 1: single-dose of test formulation+single-dose of reference formulation

Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.

DRUG

Group 2: single-dose of reference formulation+single-dose of test formulation

Eltrombopag olamine is a small molecule non peptide thrombopoietin receptor agonist.

Trial Locations (1)

Changchun University of Traditional Chinese Medicine Affiliated Hospital, Changchun